TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated Nov. 17, 2025 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that TONMYATM (cyclobenza

-- STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm gut-restricted profile of ontunisertib in FSCD patients -- -- Positive efficacy signals observed for several exploratory clinical endpoints -- -- Ongoing open-label extension study supports longer-term safety and tolerability profile observed to date -- November 17, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants comp

Nov. 17, 2025 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2

-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need -- Following CTA approval, Phase 1 ATLAS trial planned to begin in 2026 Nov. 17, 2025 -- T-knife Therapeutics, Inc., a biopharmaceutical company developing next-generation T cell therapies to fight cancer, today announced the filing of a Clinical Trial Application (CTA) to begin the Phase 1 ATLAS t

FDA grants Fast Track designation to DPTX3186, Dewpoint’s first in class condensate modulator for gastric cancer Designation provides increased FDA engagement, rolling review eligibility, and potential for accelerated development Follows recent IND opening, and Orphan Drug Designation, as Dewpoint prepares to initiate a Phase 1a/2a clinical trial this year Nov. 17, 2025 -- Dewpoint Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation

Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1D If approved, Teizeild would become the first disease-modifying T1D therapy in the EU November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a p

Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a activators patent for acute heart failure was granted in Isreal Nov. 14, 2025 -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating compan

Nov. 13, 2025 -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (tirzepatide) from Eli Lilly and

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results Nov. 14, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including

Nov. 14, 2025 -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces the closing of the first tranche (the “First Tranche”) of its non-brokered private placement (the “Offering”), previously announced on November 6, 2025. Gross proceeds from the First Tranche totaled CAD $177,000 from the sale of 2,528,752 units (the “Units”) at an issue price of CAD $0.07 per Unit. Certain insiders of the Company participated